Getty Images Recent findings suggest that it may be possible to spare patients unnecessary exposure to radiation. Recent findings provide clues to the optimal timing and indications for the use of ...

This study, innovaTV 301, was a phase 3, multinational, open-label trial (n = 502) of tisotumab vedotin as a second- or third-line therapy compared with the investigator's choice of chemotherapy. The ...